Lataa...
Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis
Ruxolitinib is a recommended second-line treatment for the prevention of thrombosis in patients with polycythemia vera who become resistant or intolerant to hydroxyurea; however, evidence regarding its efficacy in terms of thrombosis reduction is uncertain. We searched Medline, Embase, and archives...
Tallennettuna:
| Julkaisussa: | Blood Adv |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Hematology
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6988397/ https://ncbi.nlm.nih.gov/pubmed/31985808 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001158 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|